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Purpose of review
The evaluation of disease activity in axial spondyloarthritis (SpA) is complex and
multifactorial. Moreover, patients and physicians have different perspectives of the
disease and none of the current single-item or combined indexes adequately unifies
both perspectives. Recent efforts have been made to improve disease activity
measurement in axial SpA.
Recent findings
The Assessment of Spondyloarthritis international Society (ASAS) embraced the
project of developing a new index for disease activity measurement in axial SpA: the
Ankylosing Spondylitis Disease Activity Score (ASDAS). The process closely mimicked
the development of the Disease Activity Score in rheumatoid arthritis. Cut-offs for
disease activity states and response levels have also been developed. Good
performance of ASDAS has been shown in several international datasets, including
randomized controlled trials and observational cohorts.
Summary
The ASDAS is a well balanced index covering the underlying construct of disease
activity and designed to avoid redundancy. It is a feasible and valid measurement
instrument with a very good performance compared to existing tools. The ASDAS and
its cut-off values may help clinicians and researchers to better assess patients with axial
SpA, more reliably determine their disease activity status, the effectiveness of
treatments and whether they are providing clinically meaningful improvement.
Keywords
ankylosing spondylitis, disease activity, outcomes research, spondyloarthritis, validity
Curr Opin Rheumatol 23:000–000
 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins
1040-8711Introduction
Patients with axial spondyloarthritis (SpA) differ in
the predominance of individual clinical manifestations.
This phenotypic heterogeneity of the disease makes the
evaluation of disease activity in axial SpA complex and
prone to misrepresentation, if individual domains are
used to evaluate disease activity.
The Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) aggregates single-item variables (fatigue, back
pain, joint pain/swelling, enthesitic points, intensity and
duration of morning stiffness) in a single score, and has
been the most widely used measure of disease activity
in axial SpA [1]. However, the BASDAI measures only
part of disease activity, only includes patient reported
measures, does not weight individual clinical manifes-
tations (the variables are simply summed without taking
the relative importance and dependency into account),
does not take into account variable redundancy (the
phenomenon that separate variables cover the same
aspect of the disease and may have high correlation)
and lacks specificity for inflammatory processes. More-
over, BASDAI is fully patient-oriented, and patients andopyright © Lippincott Williams & Wilkins. Unauth
1040-8711  2011 Wolters Kluwer Health | Lippincott Williams & Wilkinsphysicians have different perspectives of the disease [2].
Furthermore, a modified version of the BASDAI contain-
ing no questions about peripheral arthritis and enthesitis
(mini-BASDAI) has also been tested and did not perform
better than the original version [3,4].
Therefore, a new instrument to measure disease activity
in axial SpA was required. This new instrument should
be truthful, discriminative and feasible, and should
include domains/items that are considered relevant by
both patients and physicians.
The literature between January 2009 and January 2011
was searched for new measurement instruments for clinical
disease activity in axial SpA. Only articles about the
Ankylosing Spondylitis Disease Activity Score (ASDAS)
were found and therefore this review will only focus on
this new assessment tool.Development of the Ankylosing Spondylitis
Disease Activity Score
The Assessment of Spondyloarthritis international
Society (ASAS) embraced the project of developing aorized reproduction of this article is prohibited.
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 The evaluation of disease activity in axial spondylo-
arthritis (SpA) is complex and multifactorial.
 Currently used single variable parameters and the
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) only cover a part of the construct of
disease activity.
 The Ankylosing Spondylitis Disease Activity Score
(ASDAS) is a new disease activity index that
maximizes the available information.
 The ASDAS and its cut-off values may help
clinicians and researchers to better assess, manage
and investigate patients with axial SpA.new composite measure for disease activity in axial SpA.
The first step in developing this new tool was a Delphi
process among ASAS members through which domains
and variables describing disease activity in axial SpA were
identified (Table 1), followed by a meeting to resolve
outstanding problems. This process ensured content
validity. The items selected in the Delphi exercise were
then further tested in International Study of Starting anti-
TNF agents in AS (ISSAS) [5], a large international
database of ankylosing spondylitis (AS) patients, in which
rheumatologists determined which patients in their
opinion should start a TNF-blocker after a regular clinical
visit. Principal component analysis with the 11 principal
components shown in Table 1 was performed [the Bath
AS Functional Index (BASFI) was excluded], followed
by discriminant function analysis on factor loadings to
determine the best composition of factors [6]. This
methodology ensured face and construct validity.
On the basis of these analyses, the following five variables
were selected and combined in one formula: back
pain (BASDAI question 2), duration of morning stiffness
(BASDAI question 6), patient global assessment, eryth-
rocyte sedimentation rate (ESR) and C-reactive protein
(CRP). Three alternative formulas were derived to meet
criticism about the feasibility of including two acute
phase reactants simultaneously and about the duplicity
of including patient global assessment and other patient
reported outcomes in the same formula. Therefore, in the
alternative formulas, ESR (or CRP) was replaced by peri-
pheral pain/swelling (BASDAI question 3) and patient
global was replaced by fatigue (BASDAI question 1).
The four formula options were tested in ISSAS (from
which they were developed) and Outcome in ASopyright © Lippincott Williams & Wilkins. Unautho
Table 1 Domains and variables selected for inclusion in the
analysis to derive a disease activity index in axial spondylo-
arthritis
Domains Variables
Pain Back pain (BASDAI question 2)
Spinal pain
Peripheral pain (BASDAI question 3)
Inflammation Back pain at night





Patient global Patient assessment of global disease activity
Peripheral signs Swollen joint count
Tender enthesis count
Fatigue Fatigue (BASDAI question 1)
Reproduced with permission from Table 1 of [6]. BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
Spondylitis Functional Index.
a After formal discussion, BASFI was excluded from further analysis
because physical function is a reflection/consequence of both disease
activity and damage and should not be included in an instrument which
measures disease activity.International Study (OASIS) as an independent dataset
[7], and standardized mean differences (a value that
quantifies the number of standard deviations by which
two groups differ) were calculated (Table 2) [6].
In ISSAS, the discriminator was the rheumatologists’
judgement that a patient required a TNF-blocking drug
(yes vs. no) and in OASIS, the discriminator was patient
and physician global assessment of disease activity at
baseline (high vs. low) [6]. Results showed that all four
ASDAS formulas performed similarly and better than the
BASDAI and single-item variables (Table 2).
Further validations were carried out in the Norwegian
DMARD (NOR-DMARD) [9] registry and in data
from four randomized clinical trials (RCTs) in AS using
TNF-blockers (Table 2) [8]. In NOR-DMARD, the
following discriminators were used: physician global
assessment at baseline and after 6 months (high vs.
low), patient in acceptable symptom state (PASS) after
6 months (yes vs. no), patients considering themselves
considerably improved after 3 months (yes vs. no) and
impact of treatment after 3 or 6 months (TNF-blocker vs.
DMARD). In the RCTs-merged population, discrimi-
nation between patients treated with TNF-blockers and
placebo and sensitivity to change (using Guyatt’s effect
size) were tested [8]. Again the four ASDAS formulas
performed very well: they were highly discriminatory in
differentiating patients with different levels of disease
activity and in differentiating those with different
levels of change. Notably, the ASDAS performed better
than the BASDAI and single-item variables in all settings:
patient-based or physician-based, reflecting status or
change, normal or raised CRP levels and in the presence
or absence of peripheral arthritis (Table 2).
In summary, at this point, a weighted and highly dis-
criminative continuous disease activity index for axial
SpA based on items obtained by consensus had been
statistically constructed and validated [6,8]. On
the basis of feasibility, the ASAS membership selected
the ASDAS containing CRP as acute phase reactant asrized reproduction of this article is prohibited.


































































Table 2 Discriminatory ability of several indexes/variables, using the approach of standardized mean differencea










































ASDAS-CRP 1.07 2.22 1.10 0.95 1.33 1.65 1.85 1.33 1.15 1.50 (2.4) 1.55 1.57 1.49 1.49
ASDAS-ESR 1.14 2.35 1.48 0.90 1.55 1.96 1.67 1.40 1.10 1.51 (2.2) 2.01 1.53 1.50 1.50
ASDAS-CRPþESR 1.18 2.24 1.36 0.99 1.47 1.87 1.85 1.42 1.12 1.59 (2.5) 1.77 1.67 1.59 1.55
ASDAS-fatigue 1.14 1.51 1.32 0.93 1.37 2.00 1.85 1.37 1.02 1.56 (2.4) 1.71 1.64 1.64 1.45
BASDAI 0.81 1.79 0.75 0.55 0.63 1.42 2.05 1.24 0.94 1.09 (1.5) 1.50 1.04 1.05 1.12
BASDAI 1 0.89 0.90 0.90 0.07 0.07 1.21 1.68 0.52 0.24 0.77 (1.1) 1.05 0.70 0.76 0.76
BASDAI 2 0.79 1.58 1.58 0.48 0.65 0.92 1.50 1.32 0.97 0.99 (1.6) 1.24 0.94 0.99 0.98
BASDAI 3 0.16 1.10 1.10 0.52 0.57 1.06 1.00 0.58 0.06 0.63 (0.8) 1.18 0.55 0.57 0.73
BASDAI 4 – – – – 0.45 1.06 1.70 0.96 0.80 0.75 (1.0) 0.71 0.76 0.67 0.89
BASDAI 5 – – – – 0.42 1.12 1.41 1.11 0.78 1.04 (1.6) 1.17 1.02 0.97 1.16
BASDAI 6 0.41 0.82 0.82 0.43 0.28 1.05 1.43 1.20 1.08 0.82 (1.5) 0.67 0.85 0.91 0.67
BASDAI 5/6 – – – – 0.37 1.17 1.46 1.27 1.02 1.03 (1.7) 1.15 1.05 1.04 1.01
Patient global 0.81 – – – 0.76 1.43 – 1.13 0.95 1.09 (1.6) 1.13 1.08 0.98 1.24
Physician global – – – – – – 0.76 0.97 1.06 1.24 (1.8) 1.22 1.25 1.22 1.24
ESR – – – – 1.11 1.26 0.30 0.64 0.43 1.17 (1.5) 1.07 1.27 1.09 1.26
CRP – – – – 1.30 1.14 0.35 0.69 0.56 0.83 (1.5) 0.01 0.97 0.67 1.06
Ln (CRPþ1) 0.71 0.69 1.24 0.88 – – – – – – – – – –
H(ESR) 0.82 0.63 2.18 0.81 – – – – – – – – – –
Reproduced with permission from Tables 6–9 of [6] and Tables 3–6 of [8]. ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; M, months; PASS, patient acceptable symptom state; PhGA, physician global assessment of disease activity; PtGA, patient global assessment of
disease activity; RCTs, randomized controlled trials. (PASS explored by the following question: ‘Is your current condition satisfactory considering your general level of functioning and pain?’; Considerable
improvement explored by the following question: ‘Did you experience considerable improvement since the start of your treatment?’.)
a Standardized mean difference is the difference in the group means divided by the pooled standard deviation of the group means – the higher the value, the greater the discriminatory capacity between
subgroups of patients with low vs. high disease activity according to various definitions and between various levels of change after treatment.
b For the RCTs, the Guyatt’s effect size is also calculated between brackets (mean change in the anti-TNF group divided by the standard deviation of the change in the placebo group, a measure of
sensitivity to change – the higher the value, the greater the sensitivity to change).
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4 Spondyloarthropathies
Table 3 The two Ankylosing Spondylitis Disease Activity Score formulas: Ankylosing Spondylitis Disease Activity Score-C-reactive
protein (preferred) and Ankylosing Spondylitis Disease Activity Score-erythrocyte sedimentation rate (alternative)
ASDAS-CRP 0.12back painþ0.06duration of morning stiffnessþ0.11patient globalþ0.07peripheral pain/swellingþ
0.58 ln(CRPþ1)
ASDAS-ESR 0.08back painþ0.07duration of morning stiffnessþ0.11patient globalþ0.09peripheral pain/swellingþ
0.29H(ESR)
ASDAS, Ankylosing Spondylitis Disease Activity Score; H(ESR), square root of the erythrocyte sedimentation rate (mm/h); ln(CRPþ1), natural
logarithm of the C-reactive protein (mg/l)þ1. Back pain, patient global, duration of morning stiffness and peripheral pain/swelling are all assessed on a
visual analogue scale (from 0 to 10 cm) or on a numerical rating scale (from 0 to 10). Back pain, BASDAI question 2: ‘How would you describe the
overall level of AS neck, back or hip pain you have had?’ Duration of morning stiffness, BASDAI question 6: ‘How long does your morning stiffness last
from the time you wake up?’ Patient global: ‘How active was your spondylitis on average during the last week?’ Peripheral pain/swelling, BASDAI
question 3: ‘How would you describe the overall level of pain/swelling in joints other than neck, back or hips you have had?’. Reproduced with
permission from Table 1 of [10].the preferred version and the one with ESR as the
alternative version (Table 3).Figure 1 Ankylosing Spondylitis Disease Activity Score cut-offs
Cut-offs for disease activity states
Cut-offs for improvement scores (response levels)





















(a) Cut-offs for disease activity states. (b) Cut-offs for improvement
scores (response levels). Reproduced with permission from Fig. 1 of
[11].Ankylosing Spondylitis Disease Activity Score
cut-offs
The next step to consolidate the ASDAS as an instrument
to measure disease activity in AS was the development of
cut-offs for ‘disease activity states’ and ‘improvement
scores’ (‘response levels’).
‘Disease activity states’ are defined as measurable, cross-
sectional levels of disease activity. They are important
for supporting decisions about entry into clinical trials,
for supporting treatment changes and for defining
therapeutic goals. ‘Response levels’ are defined as change
scores in a continuous variable (with cut-points for each
response level). They help to determine whether treat-
ments really work, that is, whether they actually produce
clinically important improvement, allowing investigators,
clinicians, regulators and patients to determine the
efficacy (or lack thereof) of a given intervention and to
communicate about response using the same metric.
To define the cut-offs, receiver operating characteristic
(ROC) analysis against several external criteria was
performed, using data from the NOR-DMARD registry
[11]. ASAS members debated and voted to define four
disease activity states: inactive disease, moderate disease
activity, high disease activity, and very high disease
activity. In the ROC analysis, both the patient and
physician global assessments at predefined levels (<1,
<3 and >6 on a 0–10 point scale) were used as external
constructs for ‘inactive disease’, to separate ‘moderate’
from ‘high disease activity’ and for ‘very high disease
activity’, respectively. Additionally, for determining the
cut-off for ‘inactive disease’ ASAS partial remission
criteria were also used as an external anchor. Several
approaches were used to determine the optimal cut-off
and the final choice was made on clinical and statistical
grounds. Based on the results, the following cut-offs were
selected: ASDAS less than 1.3 to define ‘inactive disease’,
ASDAS greater or equal to 1.3 and less than 2.1 to defineopyright © Lippincott Williams & Wilkins. Unautho‘moderate disease activity’, ASDAS greater or equal to
2.1 and less than or equal to 3.5 to define ‘high disease
activity’, and ASDAS greater than 3.5 to define ‘very high
disease activity’ (Fig. 1a).
Regarding improvement scores, the external criterion
that was used for the ROC analysis was a ‘global rating
of change’, available in NOR-DMARD. This is a Likert-
type scale scored for health change by the patient,
according to five categories: ‘much better’, ‘better’,
‘unchanged’, ‘worse’ and ‘much worse’. Selected cut-offs
for improvement scores were a change of at least 1.1 units
for ‘clinically important improvement’ (defined by using
the patient’s report of being ‘better’ or ‘much better’ since
the start of treatment as an external criterion) and a changerized reproduction of this article is prohibited.
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Table 4 Percentage of patients achieving Ankylosing Spondylitis Disease Activity Score improvement criteria and classical
improvement criteria in the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy trial
Criterion ASDAS-CRP, TNF-blocker vs. placebo
3 months x2 (P-value)a 6 months x2 (P-value)a
DASDAS 1.1 71.3 vs. 19.6 45.9 (<0.001) 69.3 vs. 23.2 36.3 (<0.001)
ASAS20 64.0 vs. 25.0 25.6 (<0.001) 63.2 vs. 21.4 29.2 (<0.001)
BASDAI50 50.6 vs. 10.7 27.6 (<0.001) 51.5 vs. 12.5 26.1 (<0.001)
DBASDAI 2 60.4 vs. 23.2 23.1 (<0.001) 62.6 vs. 19.6 30.8 (<0.001)
DASDAS 2.0 43.9 vs. 3.6 30.4 (<0.001) 50.9 vs. 5.4 36.3 (<0.001)
ASAS40 50.6 vs. 16.1 20.5 (<0.001) 47.2 vs. 14.3 19.1 (<0.001)
ASDAS inactive disease 25.8 vs. 1.8 15.2 (<0.001) 31.9 vs. 0 23.4 (<0.001)
ASAS partial remission 21.5 vs. 1.8 11.8 (0.001) 23.3 vs. 1.8 13.2 (<0.001)
ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASSERT, Ankylosing
Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP,
C-reactive protein. Reproduced with permission from Tables 3 and 5 of [11].
a The x2 is a statistic used to compare the various measures – the higher the x2 value, the greater the discriminatory capacity.of at least 2.0 units for major improvement (defined by
using the patient’s report of being ‘much better’ since the
start of treatment as an external criterion) (Fig. 1b).
The above-defined cut-offs were then cross-validated in
NOR-DMARD at different time-points and in AS Study
for the Evaluation of Recombinant Infliximab Therapy
(ASSERT), a database of AS patients participating in
a RCT with a TNF-blocker. Results showed a clear shift
of treated patients from higher towards lower disease
activity states. Moreover, the comparison between the
active and placebo groups in the RCT population showed
that ASDAS improvement scores were more dis-
criminative than classical improvement criteria (ASAS20,
ASAS40, BASDAI50 and DBASDAI of at least 2 units) and
also that ASDAS inactive disease was more discriminative
than ASAS partial remission criteria (Table 4).
The cross-validation process was performed taking
into account the aspects of truth and discrimination of
the OMERACT filter and in May 2010, the results were
presented and discussed in the OMERACT community.
The proposed cut-offs, which are applicable both to
ASDAS-CRP and ASDAS-ESR (although the two
ASDAS scores are not interchangeable), were scrutinized
and obtained the endorsement of this international group
of people with a broad background including clinicians,
researchers and patients [10].Further validation of the Ankylosing
Spondylitis Disease Activity Score
The construct validity and responsiveness of the ASDAS
have been assessed in several recent studies. In a Danish
cohort of patients with axial SpA treated with TNF-
blockers (BIOSPA), Pedersen et al. [12] showed that
ASDAS-CRP had the highest responsiveness (higher
effect size and standardized response mean) compared
with various conventional clinical measures, namely
the BASDAI, single-item patient reported outcomes,opyright © Lippincott Williams & Wilkins. Unauthphysician global, CRP, spinal mobility and enthesitis
scores, MRI lumbar spine and sacroiliac joints inflam-
mation scores, MRI sacroiliac joints chronicity score and
tender/swollen joint counts. This study also confirmed
that the ASDAS had a more balanced correlation with
patient and physician global assessments than BASDAI,
which is only driven by patient reported measures.
Interestingly, in this study, ASDAS changes not only
correlated significantly with changes in other measures
of disease activity [such as BASDAI (rho¼ 0.76) and CRP
(rho¼ 0.79)], but also correlated with changes in MRI
inflammation scores at the sacroiliac joints (rho¼ 0.46) or
sacroiliac joints plus lumbar spine (rho¼ 0.34), contrary to
BASDAI and CRP, in which the correlation with changes
in MRI inflammation scores was not statistically signifi-
cant. In a Turkish study [13], the ASDAS-CRP and
ASDAS-ESR also performed better than patient-reported
measures (including BASDAI) and acute-phase reactants,
discriminating better between high and low disease
activity status, and performance was not affected by
the presence of peripheral arthritis. In another Turkish
cohort of patients with AS, Aydin et al. [14] showed that
all ASDAS formulas correlated well with physician global,
patient-reported outcomes and acute phase reactants,
and performed well in discriminating between patients
requiring TNF-blockers or not, and between patients
with high vs. low disease activity according to physician’s
assessment. In a Canadian population of patients with
axial psoriatic arthritis, Eder et al. [15] reported that
the ASDAS-CRP and ASDAS-ESR correlated well
with patient and physician global, and showed good
discriminative ability between high and low disease
activity states (according to patients, physician and treat-
ment decisions). However, in both these two last studies
[14,15], BASDAI performance was very similar to (but not
better than) the ASDAS. Recently, it was also reported
that ASDAS-CRP performed well in patients with AS
treated with TNF-blockers over 8 years [16] and in
patients with active nonradiographic axial SpA treated
with adalimumab and retreated after interruption oforized reproduction of this article is prohibited.
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analysis of the performance of various efficacy measure-
ments in AS, using data from the AS Study Comparing
Enbrel with Sulphasalazine Dosed Weekly (ASCEND)
trial [18], the ASDAS-CRP again showed the best dis-
criminatory capacity, followed by the objective measure
CRP. Overall subjective outcome measures, such as
nocturnal back pain, back pain, physician global assess-
ment of disease activity and BASDAI, showed somewhat
lower discriminatory capacity than ASDAS (or CRP
alone) [18]. Of note, it has also been reported that high
sensitivity CRP testing increases the sensitivity and
responsiveness of ASDAS-CRP [11,19]. In the past, it
had already been noted that high sensitivity CRP could
be superior to standard CRP in assessing disease activity
in axial SpA [20].
The ASDAS cut-off for ‘inactive disease’ (a remission-
like state) may be an important guideline for achieving a
therapeutic aim. Compared with ASAS partial remission
criteria, ASDAS inactive disease has the advantage of
being independent of BASFI: patients with a lot of
structural damage who (as a consequence) have a high
BASFI may never achieve ASAS partial remission,
whereas they may more easily achieve inactive disease.
In the ASDAS cut-offs validation study [11], more
patients achieved the inactive disease state compared
with ASAS partial remission while retaining higher
discriminatory capacity between treatment groups
(Table 4). Similar results were found in an independent
cohort (ATLAS – Adalimumab Trial evaluating Long-
term efficacy and safety for AS), in which potential causes
of observed differences in response rates were investi-
gated over a 5-year period [21]. This study showed that
patients who achieved ASDAS inactive disease but not
ASAS partial remission had higher baseline BASFI and
modified Stoke AS Spine Score (mSASSS) values,
compared with those who achieved both disease activity
states’ definitions. BASFI was the most frequently
observed ASAS component to have not met the required
value of less than 2 (range 0–10) in the subgroup
achieving ASDAS inactive disease but not ASAS partial
remission. Even higher baseline BASFI and mSASSS
values were noted for those who did not fulfil either
criterion. These observations confirmed that ASDAS
inactive disease detects more patients in a remission-like
state and allows better differentiation between active
treatment and placebo. This is likely because of the inclu-
sion of BASFI in ASAS partial remission, which may not
reflect response to effective therapies if irreversible damage
and functional disability are present [21].Truth, discrimination and feasibility
In summary, the ASDAS is an index that maximizes
the available information (the signal) and reduces theopyright © Lippincott Williams & Wilkins. Unauthorandom error associated with measurement (the noise).
It performs well methodologically and has high face,
content and construct validity, in both clinical practice
and research settings. Moreover, it is a highly discrimina-
tory instrument for assessing disease activity in axial SpA.
ASDAS good performance as a continuous measure
and as a state/response measure was shown in various
international datasets, including RCTs and observational
cohorts.
Feasibility is another important aspect for the success of
an outcome measure [22]. Although the ASDAS includes
logarithmic (CRP) or root (ESR) transformed factors, the
feasibility of such formulae has already been proven
by the wide use and successful implementation of the
Disease Activity Score (DAS) in rheumatoid arthritis,
both for research and clinical practice. This has largely
been promoted by the disseminated use of online and
hand-held calculators. The ASDAS-CRP and ASDAS-
ESR formulas are actively being incorporated in hand-
held calculators and an ASDAS online calculator is
already available at the ASAS website (www.asas-group.
org). A quick ASDAS calculator paper-form with tables
for quick arithmetic conversion of ASDAS items is
also available at the website, as an alternative method
to electronic devices. Moreover, it should be noted that
the ASDAS is less time-consuming than the DAS because
it does not involve joint counts. Therefore, ASDAS
seems to be a feasible and practical tool that could easily
be adopted by clinicians.Conclusion
A new disease activity index in axial SpA has been
developed. The ASDAS and its cut-off values may help
clinicians to better assess patients with axial SpA, more
reliably determine their disease activity status, the effec-
tiveness of treatments and whether they are providing
clinically meaningful improvement. The higher dis-
criminatory capacity and sensitivity to change of the
ASDAS may have important implications in reducing
the sample size calculation for clinical trials. The use
of the ASDAS as the primary outcome in a trial with a
TNF-blocker reduces the number of required patients by
about 40% in comparison to the use of the BASDAI while
maintaining similar power. The ASDAS will also allow
clinicians, investigators, regulators and patients to con-
tinue communicating about treatment response using
the same metric and will facilitate studying the impact
of disease activity states on prognosis.Acknowledgements
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